Informa Pharma Intelligence and goBalto Partner to Enrich Clinical Trial Data for Clients
Citeline, powered by Informa Pharma Intelligence, is being integrated with goBalto's Select to provide broader knowledge of clinical trials and investigators in order to optimize the site selection process
NEW YORK, June 19, 2017 (GLOBE NEWSWIRE) -- Today, Citeline, the gold standard in drug, trial and clinical investigator intelligence, powered by Informa Pharma's Business Intelligence, and goBalto, the industry-leader in cloud-based clinical study startup solutions, are announcing a partnership to integrate data from Citeline's Trialtrove and Sitetrove solutions into goBalto's Select, for optimizing site selection and accelerating clinical trial success.
By incorporating intelligence from Citeline, mutual goBalto and Citeline clients can access the most comprehensive collection of global clinical trials, clinical trial investigator profiles and drug development pipelines. By directly including Citeline data with client's internal assets in goBalto Select and other third-party databases, companies can realize a more robust, data-driven approach to accelerate the startup phases of clinical trials and optimize site selection - all in a single platform solution.
Trialtrove provides the industry's most robust coverage of the global clinical trial landscape and is the most comprehensive source for the complete history of individual clinical trials, while Sitetrove offers access to nearly 400,000 clinical investigators and 150,000 trial sites to help greatly improve clinical trial success. goBalto's award-winning Select offers a data-driven approach by weighing selection and performance variables to reduce the risks of selecting non-active, non-enrolling (NANE) sites and target populations ideally suited to studies in clinical trials. goBalto and Citeline client's will greatly benefit from the increased depth and breadth of data available to them allowing for faster and more accurate site selection decisions.
Jason Tse, Head of Strategic Partnerships at Pharma Intelligence said, "We're excited to team up with goBalto, knowing that our clients will benefit from their clinical trial operational expertise. Additionally, the partnership with goBalto further emphasizes our strategy to drive value and growth for our clients through strategic partnerships. Providing access to our data and insights through goBalto's platform helps expand knowledge of clinical trials and clinical investigator/site history to help achieve better results. Research and decisions in clinical trials can be made easier, faster and better through this partnership."
Sujay Jadhav, CEO of goBalto explained, "Informa Pharma Intelligence has a robust trove of data and deep understanding of clinical trials that our customers will find extremely valuable. Our partnership will speed up clinical trials and get much needed therapies to patients faster."
This partnership is kicking off ahead of the Drug Information Association (DIA) 2017 Annual Meeting taking place in Chicago on June 18. Both Informa Pharma Intelligence and goBalto will be attending the event at booth #'s 1148 and 1854, respectively. If you are interested in speaking with Informa Pharma Intelligence and goBalto at DIA please reach out to Robert.email@example.com.
Citeline, part of Informa's Pharma Intelligence vertical, is the world's most comprehensive source of real-time R&D intelligence for the pharmaceutical industry, featuring an unmatched intelligence collection and enrichment of global clinical trials, clinical trial investigator profiles and drug development pipelines.
Citeline is the R&D Intelligence arm of Informa's Pharma Intelligence vertical, one of the world's leading providers of drug, device, company, clinical trial and market intelligence in the pharma and medtech markets. For more information, visit https://pharmaintelligence.informa.com/
goBalto is the industry leader in cloud-based study startup software for the global life sciences industry, offering the only complete end-to-end platform for starting clinical trials, from site identification, feasibility assessment and selection through to activation, with comprehensive metrics to track adherence to timelines and budget. Committed to accelerating clinical trials through innovation, product excellence, and customer success, goBalto works with three of the top five CROs and more than two-thirds of the top 25 pharmas. Our customers include: Allergan, Covance, CMIC HOLDINGS, Genentech Roche, ICON, INC Research, Novartis, and PSI CRO. goBalto is headquartered in San Francisco, with offices in Philadelphia and Singapore. For more information, visit www.gobalto.com.
For more information, please contact:
Allie Tedone/Danielle Cecchini
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Informa Business Intelligence via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Nitinat Provides Progress Report on Carscallen and Jasper Properties23.4.2018 22:38 | Pressmeddelande
TORONTO, April 23, 2018 (GLOBE NEWSWIRE) -- Nitinat Minerals Corp. (the "Company") (TSXV:NZZ) (Frankfurt:04U1) is pleased to announce that the work on its 100% owned Carscallen Property is underway and is going as planned. The Corporation will be providing details on an ongoing basis as the work progresses and details become available. The Corporations is also pleased to announce the initiation of a work program on its 100% owned Jasper Property which is located inland from the western shore of Vancouver Island, B.C., roughly 80 kilometers Northwest of Victoria, lying in the area of Nitinat Creek and Lake and is accessed by logging roads coming in from the North. The Jasper Property consists of the Jas 3 legacy mineral claim and eight unnamed cell mineral claims that together comprise nine contiguous claims that cover 3978 hectares. The Jasper Property is 100% owned and operated by the Company. The Highly Visible mineralized showings on the Jasper claims lie in a rugged forested area a
Atico Reports Consolidated Financial Results for 201723.4.2018 22:30 | Pressmeddelande
(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX-V:ATY) (OTC:ATCMF) today announced its financial results for the year ended December 31, 2017, posting income from mining operations of $15.32 million and a net income of $4.04 million. Production for the year at Atico's El Roble mine totaled 20.6 million pounds ("lbs") of copper and 10,923 ounces ("oz") of gold in concentrates at a cash cost(1) of $1.45 per payable pound of copper produced(2). Fernando E. Ganoza, CEO and Director, commented, "We are pleased to report our strongest year to date both operationally and financially, as the Company concluded 2017 exceeding nearly all set objectives for the year. Operationally, we delivered above our higher end guidance while further increasing operational standards at El Roble. Financially, we have delivered a record year in most metrics while significantly s
Luxoft Develops 'Blockchain Adapter' for a Business Process Management Tool on Appian's Platform23.4.2018 21:58 | Pressmeddelande
Luxoft to unveil healthcare use case for blockchain adapter at Appian World in Miami, April 23-25 (Booth 16) Zug, SWITZERLAND and Reston, VA -- 24 April, 2018 - Luxoft Holding Inc. (NYSE:LXFT), a global IT service provider, today announces it has built a blockchain adapter for Appian's (NASDAQ:APPN) rapid application development platform. It is now available exclusively to businesses using Appian's Business Process Management (BPM) tool and will allow its users to integrate a blockchain network into their day-to-day business processes, creating a secure, digital environment that facilitates data sharing. "The launch of this adapter is about helping businesses realise the potential of blockchain by making it easier to use," said Vasiliy Suvorov, Vice President of Technology Strategy at Luxoft. "Problems integrating blockchain into existing in-house systems are often the biggest obstacles to its adoption. Now, by integrating blockchain into a BPM, a business can leverage the benefits of
Mitratech Acquires ThinkSmart LLC to Create Industry-First, End-to-End Legal Operations Platform23.4.2018 17:00 | Pressmeddelande
Integration of ThinkSmart's agile workflow software into Mitratech's TeamConnect platform sets a new global standard for legal and compliance innovation and excellence LAS VEGAS, April 23, 2018 (GLOBE NEWSWIRE) -- Today, Mitratech a leading provider of legal and compliance software, announced the acquisition of ThinkSmart LLC, creating an end-to-end platform designed to transform legal operations into a center of innovation and excellence. With the addition of ThinkSmart and the ThinkSmart Automation Platform (TAP), Mitratech's TeamConnect platform can now bring people, processes and information together like never before, by leveraging TAP's easy-to-use workflow automation engine to extend TeamConnect's reach across the entire enterprise. In today's rapidly evolving legal landscape, there is a need for a truly evolutionary Enterprise Legal Management (ELM) platform. ELM systems have delivered on the operational efficiencies, centralized view of information, security and data integrity
Vricon unveils new solution at GEOINT 2018: Vricon Precision 3D Registration (P3DR)23.4.2018 16:20 | Pressmeddelande
Precise, accurate, georegistered GEOINT data for analytics and visualization-at a global scale McLean, Virginia, April 23, 2018 (GLOBE NEWSWIRE) -- Vricon is pleased to announce that it is unveiling the next in a series of GEOINT solutions - Vricon Precision 3D Registration (P3DR) - at this year's GEOINT 2018 Symposiumin Tampa, Fla. Vricon P3DR is a software suite designed to automatically georegister imagery, regardless of collection platform, against the most accurate 3D geospatial foundation available, The Globe in 3D. P3DR can be implemented as a real-time processing workflow for imagery feeds without the need for GPS location, heading information, or ground control points. "While we've always been able to perform georegistration of individual data sets using our 3D models as an accurate foundation, Vricon P3DR takes this capability to a whole new level," said Magnus Brege, Vricon CEO. "Our users now have multiple options for where and when they can automatically georegister their
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA23.4.2018 14:15 | Pressmeddelande
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ABO-102, the Company's AAV-mediated gene therapy for the treatment of Sanfilippo syndrome Type A (MPS IIIA), a rare autosomal-recessive lysosomal storage disease. "We are encouraged to have received the first gene therapy RMAT designation in MPS IIIA and look forward to further collaborating with the FDA to determine next steps in the development pathway for ABO-102," said Carsten Thiel, Ph.D., CEO of Abeona Therapeutics. "This action further reinforces the clinical significance in the data observed in the ongoing P
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum